Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 7
Submit an article Journal homepage
221
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial

Sebastian GrosickiDepartment of Hematology and Cancer Prevention in Chorzow, Faculty of Health Sciences Bytom, Silesian Medical University in Katowice, Katowice, Poland; View further author information
,
Ewa Lech-MarandaDepartment of Hematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; View further author information
,
Kanakasetty Govind BabuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, HCG Hospitals Bangalore, Bengaluru, India; View further author information
,
Justyna RybkaDepartment of Medical Oncology, Wrocław Medical University, Wrocław, Poland; View further author information
,
Elena LitvinskayaRussian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation; View further author information
,
Javier LoscertalesHospital Universitario de La Princesa, IIS-IP, Madrid, Spain; View further author information
,
Iryna KriachokOncohematology Department, National Cancer Institute, Kiev, Ukraine; View further author information
,
Janusz KłoczkoDepartment of Hematology, Medical University of Bialystok, Poland; View further author information
,
Grygoriy RekhtmanKhmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine; View further author information
,
Wojciech HomendaDepartment of Hematology and Pomeranian Academy in Slupsk, Department of Health Sciences, The Janusz Korczak State Hospital in Slupsk, Medical University of Bialystok, Bialystok, Poland; View further author information
,
Jerzy BlonskiDepartment of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; View further author information
,
Tommaso StefanelliNovartis Pharma AG, Basel, Switzerland; View further author information
,
Ghislaine VincentNovartis Pharma S.A.S., Paris, France; View further author information
,
Hiya BanerjeeNovartis Oncology, East Hanover, NJ, USAView further author information
&
Tadeusz RobakDepartment of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; Correspondence[email protected]
View further author information
 show all
Pages 1748-1751 | Received 10 Oct 2019, Accepted 15 Feb 2020, Published online: 28 Feb 2020

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.